Details of the Drug

General Information of Drug (ID: )

• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw)
  Logarithm of the Partition Coefficient (xlogp)
  Rotatable Bond Count (rotbonds)
  Hydrogen Bond Donor Count (hbonddonor)
  Hydrogen Bond Acceptor Count (hbondacc)
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 92.6-154.1 mgh/L [1]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 9.8-11.8 mg/L [1]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4.4 h [1]
  Bioavailability: The bioavailability of drug is 25% [1]
  Clearance: The clearance of drug is 6-7 L/h [2]
  Elimination: Following oral administration, approximately 10.4 +/- 2.3% of the administered dose is excreted in the urine and 82.6 +/- 2.5% is excreted in the feces [1]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6.9 +/- 2.2 hours [1]
  Metabolism: The drug is metabolized via the hepatic CYP3A isozymes [3]
  Vd: The volume of distribution (Vd) of drug is 16.9 L [1]

References

• [1] FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use
• [2] Niu WJ, Sun T, Liu L, Liu XQ, Zhang RF, Yin L, Wang JR, Jia XF, Lu HZ, Zhong MK, Jiao Z, Zhang LJ: Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):456-465. doi: 10.1111/bcpt.13154. Epub 2018 Nov 23.
• [3] Health Canada Product Monograph: Kaletra (lopinavir/ritonavir) for oral use